Advancing the 10th Medium-Term Management Plan
First written in FY2020. 5 of 7 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023Plan period endedAnnual report
「Against this backdrop, during the current consolidated fiscal year, the final year of the 10th Medium-Term Management Plan (fiscal 2020 through fiscal 2022), the Group vigorously pursued global expansion. Dificlir, a treatment for Clostridioides difficile infection marketed mainly in Europe by Tillotts Pharma AG, made a significant contribution, resulting in substantial growth in overseas sales.」
The 10th Medium-Term Management Plan ended in fiscal 2022, and its results included global expansion and growth in overseas sales. Achievement of the plan as a whole was not explicitly stated. - FY2023-Q2RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative second quarter of the current consolidated fiscal year.」
The Company explained that there were no material changes to its management policies, management strategies or other matters, including the Tenth Medium-Term Management Plan. - FY2023-Q1RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative first quarter of the current consolidated fiscal year.」
The Company explained that there were no material changes to its management policies, management strategies or other matters, including the Tenth Medium-Term Management Plan. - FY2022-Q3RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative third quarter of the current consolidated fiscal year.」
It was explained that there were no material changes to the management policies, management strategies or other matters, including the Tenth Medium-Term Management Plan. - FY2022-Q2RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative second quarter of the current consolidated fiscal year.」
It was explained that there were no material changes to the management policies, management strategies or other matters, including the Tenth Medium-Term Management Plan. - FY2022-Q1RestatedAnnual report
「There were no material changes to the management policies, management strategies or other matters established by the Group during the cumulative first quarter of the current consolidated fiscal year.」
The Company explained that there were no material changes to its management policies, management strategies or other matters, including the Tenth Medium-Term Management Plan. - FY2020First statedAnnual report
「The Group launched its 3-year 10th Medium-Term Management Plan, beginning in fiscal 2020 and covering fiscal 2020 through fiscal 2022. The Group has positioned the 3-year period of the plan as a period for transforming its earnings structure into one capable of sustaining growth. Alongside expanding and improving the profitability of its two core businesses, consumer healthcare and prescription pharmaceuticals, the Group plans to vigorously pursue global expansion through its overseas subsidiaries and improve profitability across the Group as a whole.」
Following the 9th Medium-Term Management Plan, the Group launched the 10th Medium-Term Management Plan for fiscal 2020 through fiscal 2022. Its main initiatives are the expansion and profitability improvement of the two businesses, global expansion, and M&A and alliances.